1. Home
  2. XCBE vs PRQR Comparison

XCBE vs PRQR Comparison

Compare XCBE & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XCBE

X3 Acquisition Corp. Ltd. Class A Ordinary Shares

SELL

Current Price

$10.03

Market Cap

279.3M

Sector

N/A

ML Signal

SELL

Logo ProQR Therapeutics N.V.

PRQR

ProQR Therapeutics N.V.

HOLD

Current Price

$1.23

Market Cap

262.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XCBE
PRQR
Founded
2025
2012
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
279.3M
262.5M
IPO Year
2025
2014

Fundamental Metrics

Financial Performance
Metric
XCBE
PRQR
Price
$10.03
$1.23
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $7.78
AVG Volume (30 Days)
31.5K
★ 851.5K
Earning Date
N/A
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$8.25
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.75
$1.24
52 Week High
$10.04
$3.00

Technical Indicators

Market Signals
Indicator
XCBE
PRQR
Relative Strength Index (RSI) 67.40 22.76
Support Level $9.88 N/A
Resistance Level N/A $1.99
Average True Range (ATR) 0.00 0.09
MACD 0.00 -0.01
Stochastic Oscillator 66.67 2.08

Price Performance

Historical Comparison
XCBE
PRQR

About XCBE X3 Acquisition Corp. Ltd. Class A Ordinary Shares

X3 Acquisition Corp Ltd is a blank check company.

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

Share on Social Networks: